Related Experiment Video
Updated: May 31, 2026
06:26
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Foreword: Follow-on Biologics: Implementation Challenges and Opportunities
1Seton Hall University School of Law, Newark, New Jersey, USA.
Seton Hall Law Review
|July 12, 2011
Summary
The Biologics Price Competition and Innovation Act (BPCIA) established an abbreviated pathway for biosimilar drug approval in the US. This law presents new regulatory challenges and opportunities for the Food and Drug Administration (FDA).
Area of Science:
- Health Law
- Regulatory Affairs
- Pharmaceutical Policy
Background:
- The Patient Protection and Affordable Care Act (PPACA) of 2010 introduced the Biologics Price Competition and Innovation Act (BPCIA).
- BPCIA grants the Food and Drug Administration (FDA) authority to approve biosimilar biological products through an abbreviated pathway.
- This legislation followed a roundtable discussion on follow-on biologics at Seton Hall University School of Law.
Discussion:
- The implementation of the BPCIA presents significant regulatory challenges for the FDA.
- Understanding the distinctions between biologics and conventional drugs is crucial for developing the follow-on biologic pathway.
- The roundtable fostered international dialogue on the future of follow-on biologics in the United States.
Key Insights:
- The BPCIA aims to foster competition and innovation in the biologics market.
- The FDA faces the complex task of developing guidelines for biosimilar approval.
- The legislation signifies a major reform in the American healthcare system.
Outlook:
- Future challenges for the FDA include refining the abbreviated approval process for biosimilars.
- The development of the follow-on biologic pathway will impact drug pricing and patient access.
- Continued international collaboration and discussion are essential for navigating the evolving landscape of biologics regulation.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...